Research after commercial production refers to the legal exclusion that disqualifies research activities from being eligible for tax credits once a business component meets its primary functional and economic requirements or is ready for use. In the context of the Texas R&D tax credit, this milestone establishes a definitive boundary where qualifying experimentation ends and routine operational or manufacturing activities begin.

Technical Foundations and Statutory Evolution

The conceptual framework of the research after commercial production exclusion is primarily defined by its role as a temporal and functional barrier to tax incentive eligibility. Under the Texas Tax Code, and specifically within the administrative implementation by the Texas Comptroller of Public Accounts, the definition of “qualified research” has historically been tethered to the standards established in Section 41 of the Internal Revenue Code (IRC). This relationship is not merely referential but is foundational; the Texas legislature intended the state’s research credit to mirror the federal credit to reduce the administrative burden on taxpayers while ensuring that only genuine technological innovation is subsidized.

The exclusion arises from IRC Section 41(d)(4)(A), which stipulates that the term “qualified research” does not encompass any research conducted after the beginning of commercial production of the business component. For several years, Texas law maintained a “static” conformity to the IRC as it existed on December 31, 2011. This meant that even as federal regulations evolved, Texas taxpayers were required to adhere to the 2011 versions of the law, which lacked modern clarifications on software development, pilot models, and certain production milestones. However, the landscape shifted dramatically with the enactment of Senate Bill 2206 (SB 2206) in 2025.

SB 2206 marks a significant transition to “rolling” conformity, whereby the Texas credit calculation now follows federal law as in effect for the specific tax year for which the credit is claimed. This legislative reform has profound implications for the research after commercial production exclusion. By tying the definition of Qualified Research Expenses (QREs) directly to the amounts reported on line 48 of federal Form 6765, Texas has effectively synchronized its definition of the “production milestone” with the findings of the Internal Revenue Service (IRS). This change streamlines compliance for businesses operating in Texas, as an IRS audit determination regarding the commencement of commercial production will now carry significant weight in a Texas franchise tax review.

The evolution of these statutes reflects a broader state policy aimed at balancing aggressive economic incentivization with fiscal responsibility. Historically, the Texas R&D regime provided a dual-path incentive structure: a franchise tax credit under Subchapter M of Chapter 171 and a sales tax exemption under Section 151.3182. These two benefits were mutually exclusive, forcing taxpayers to elect one or the other. Effective January 1, 2026, SB 2206 repeals the sales tax exemption and consolidates all R&D incentives into a permanent and enhanced franchise tax credit. The expiration of the sales tax path underscores the importance of the commercial production exclusion, as the franchise credit now becomes the sole vehicle for state-level R&D support, and its criteria will be strictly scrutinized during the audit process.

The Functional Milestone of Commercial Production

Defining the precise moment commercial production begins is the most critical challenge in R&D tax compliance. Texas local state revenue office guidance clarifies that the threshold is not necessarily the first sale of a product, but rather its functional readiness. A business component—which may include a product, process, software, formula, or technique—is deemed to have entered commercial production once it meets the basic functional and economic requirements of the taxpayer.

This functional standard implies that research concludes when the “technical uncertainty” that necessitated the experimentation has been resolved. In the laboratory and experimental sense, if a taxpayer has determined that they have the capability and method to produce a design that achieves its intended result, the qualified research phase has ceased. Any work performed thereafter, even if it involves highly skilled engineering, is categorized as routine. This includes preproduction planning, “tooling up” for high-volume manufacture, and trial production runs intended to optimize the assembly line rather than the product design itself.

The Texas Comptroller utilizes a “per se” list of activities deemed to occur after the beginning of commercial production. This list is a vital tool for auditors to delineate where development ends. For example, “debugging” is specifically listed as a post-production activity. The revenue office distinguishes “debugging”—the resolution of minor glitches in an operational component—from the “correction of flaws,” which may still qualify as research if the flaw is so fundamental that it prevents the component from meeting basic requirements, thus triggering a new process of experimentation.

The transition from development to production also marks the end of the “experimentation process.” To satisfy the four-part test for qualified research, substantially all (80% or more) of the activities must involve a process of experimentation. Once commercial production begins, the nature of the work typically shifts from evaluating alternatives to resolving design uncertainties to simply monitoring established metrics. This shift in the nature of the activity provides the Comptroller with the justification to disallow expenses incurred after the product has been “released” to the manufacturing or operations department.

Local State Revenue Office Guidance and Administrative Rules

The Texas Comptroller of Public Accounts has established rigorous standards for the R&D credit through 34 Texas Administrative Code (TAC) Rule 3.599. These rules provide the granular guidance necessary to interpret the commercial production exclusion within the specific economic context of Texas. One of the most significant aspects of this local guidance is the evidentiary burden placed on the taxpayer. While federal tax law generally follows a “preponderance of the evidence” standard, Texas Rule 3.599(e) imposes a “clear and convincing evidence” requirement for establishing entitlement to the R&D credit.

Clear and Convincing Evidence

The “clear and convincing” standard means that the evidence must produce in the mind of the trier of fact a firm belief or conviction as to the truth of the allegations. In the context of the commercial production exclusion, this requires the taxpayer to demonstrate, through high-quality documentation, that technical uncertainties persisted up until the date claimed as the end of research. Auditors frequently challenge the “end date” of development by pointing to marketing materials, early customer demonstrations, or the receipt of purchase orders. If a taxpayer cannot provide contemporaneous engineering logs or project milestone reports that clearly show continued experimentation, the Comptroller may retroactively move the production start date to the earliest sign of product viability, potentially disqualifying months of research expenses.

Contemporaneous Records

Texas guidance emphasizes the necessity of contemporaneous business records. Under Rule 3.599, QREs must be supported by documentation created at the time the research was performed. This requirement is especially critical for defending against the production exclusion. Auditors will scrutinize:

• Project Narratives: Descriptions of the technological uncertainties addressed and the process of experimentation used.
• Engineering Logs: Dated entries showing testing, failures, and alternative designs.
• Personnel Records: Documentation associating specific employee hours with qualified activities vs. production support.

The Comptroller’s STAR (State Tax Automated Research) system provides additional layers of guidance through private letter rulings and policy memoranda. For instance, memorandum 202503004M clarifies that the state does not recognize the federal “group under common control” standard as a single taxpayer for Texas franchise tax purposes. Instead, each member of a combined group is treated as a separate entity for determining QREs, although the credit is ultimately claimed on a combined report. This means that if one subsidiary has entered commercial production while another is still in the R&D phase for a related component, the exclusion must be applied strictly on an entity-by-entity and project-by-project basis.

Furthermore, STAR document 9911871L provides a detailed look at how manufacturing test lab facilities are treated. It notes that quality control performance tests are considered part of the manufacturing process (and therefore post-production) unless they are necessary to resolve a design uncertainty for a specific custom order. This underscores the “functional readiness” test: if the testing is routine verification that a product meets established specs, it is excluded; if the testing is needed to discover how to achieve a result for which the method is uncertain, it may still be qualified research.

Application of the Shrink-Back and Separate Component Rules

To mitigate the broad impact of the research after commercial production exclusion, the law provides two critical interpretive mechanisms: the “separate business component” rule for production processes and the “shrink-back” rule for subset elements. These mechanisms allow taxpayers to isolate ongoing innovation even when a broader product is already in production.

Production Processes as Separate Components

IRC Section 41(d)(4)(C) and its Texas counterparts establish that any plant process, machinery, or technique used for the commercial production of a business component shall be treated as a separate business component. This is a vital distinction for Texas manufacturers. Even if a product, such as a semi-conductor chip, is being mass-produced and sold (meaning research on the chip itself is excluded), the company may still claim credits for the development of a new manufacturing process intended to increase the yield or reliability of that chip.

In this scenario, the experimentation relates to the production technique, not the product. The qualified research on the production process continues until the process meets the taxpayer’s functional and economic requirements, regardless of the commercial status of the chip being produced. This allows for continuous process improvement initiatives to be captured as qualified research, provided they meet the technological uncertainty and experimentation tests.

The Shrink-Back Rule

The shrink-back rule is a doctrine used when a taxpayer’s research activities on an overall business component fail to meet the requirements for qualified research. Instead of the entire project being disqualified, the tests are applied to the next most significant subset of elements.

Consider a motorcycle manufacturer that has been selling a particular model for three years. The overall motorcycle is in commercial production, so any general research on the bike is excluded. However, if the company decides to develop a completely new electronic fuel injection (EFI) system to replace the carburetor, the EFI system is treated as the business component. The research activities related to the EFI system constitute qualified research until the EFI system—not the entire motorcycle—meets its functional requirements and is ready for use. This rule ensures that incremental innovation and the development of new features on existing product lines are not unfairly penalized by the production status of the legacy product.

Specific Industry Interpretations: Software and Biotech

The meaning of “commercial production” varies significantly across industries, and the Texas Comptroller has issued specific guidance for software development and biotechnology to address these nuances.

Software Development

For software, the “production milestone” is often elusive due to iterative development models like Agile or DevOps. Under Rule 3.599, the Comptroller classifies software research as qualified if it involves the development of specialized technologies (AI, image processing) or the initial release of application software with new architectures or database techniques.

The exclusion for research after commercial production applies to software once the initial release meets functional requirements. Subsequent patches, minor feature additions, or updates that do not fundamentally change the architecture are deemed post-production. Furthermore, Texas maintains a strict exclusion for “Internal Use Software” (IUS). Texas defined IUS as software developed for use in the operation of the business (e.g., HR or accounting systems) rather than for commercial sale or lease. Unless the IUS meets a “High Threshold of Innovation,” all development work is excluded, regardless of whether it occurs before or after production begins.

Biotechnology and Life Sciences

In the biotech industry, the production milestone is typically tied to regulatory approval. Activities such as clinical trials (Phase I, II, and III) are clearly developmental and intended to resolve uncertainties regarding safety and efficacy. Commercial production does not begin until the drug or device is approved for sale by the relevant governing body (e.g., FDA).

However, Texas guidance clarifies that once a drug enters the market, any further “Phase IV” clinical trials or post-market surveillance studies are considered research after commercial production. These activities are viewed as routine data collection or management of a commercialized product, unless they are specifically undertaken to develop a new indication or a new delivery method, which would be treated as a separate business component.

Administrative Procedures and Audit Defense

The interplay between Rule 3.599 and Rule 3.340 creates a complex administrative environment for Texas businesses. One of the most critical recent developments is the Comptroller’s stance on credit carryforwards. Unused R&D credits can be carried forward for up to 20 consecutive reports. However, a credit cannot be carried forward if it was not legally created in the year the expenditures were made.

Verification of Closed Years

Rule 3.599(g)(5) allows the Comptroller to verify QREs in a “closed” year (a year for which the statute of limitations for refunds has expired) solely for the purpose of verifying a credit carryforward available in an “open” period. This is a powerful audit tool. An auditor can go back to a project from six years ago that created a carryforward still being used today. If the auditor finds that the project had actually entered “commercial production” earlier than the taxpayer claimed, they can reduce or eliminate the carryforward, even if they cannot assess additional tax for the closed year.

Combined Reporting Challenges

For combined groups, the “membership rule” established in the 2021 amendments creates a significant risk. If the members of a combined group change, the resulting group is viewed as a new taxable entity and cannot carry forward the R&D credits generated by the previous group composition. This “entity-level” approach means that the production status of one member’s business component can have ripple effects across the entire group’s tax planning, as unused credits may be permanently lost if a merger or restructuring occurs.

Statistical Sampling and Federal Audit Outcomes

Under SB 2206, the Comptroller’s office will follow finalized IRS audit outcomes. If the IRS determines during an audit that a taxpayer’s projects have transitioned into production earlier than reported on Form 6765, Texas will adopt those amended figures. This synchronization reduces the likelihood of “double audits” but increases the stakes of the federal R&D study. Taxpayers are advised to ensure that their federal documentation is robust enough to withstand both IRS and Texas-level scrutiny, particularly regarding project timelines and the “functional readiness” of components.

Illustrative Case Study: AeroTex Dynamics, LLC

To provide a comprehensive understanding of how the research after commercial production exclusion applies in a real-world scenario, consider the operational trajectory of AeroTex Dynamics, LLC, a hypothetical aerospace manufacturer based in Fort Worth, Texas.

Phase 1: Technological Innovation (Qualified)

In 2024, AeroTex initiates the “Hyper-Flow Project” to develop a next-generation fuel injector using a novel ceramic 3D-printing process.

• Uncertainties: The engineering team is uncertain if the ceramic material can maintain structural integrity under the 1,500 degrees F temperatures of a turbine engine. They are also uncertain if the 3D-printing resolution is sufficient to create the complex internal cooling channels required for the injector nozzle.
• Process of Experimentation: They design five different nozzle geometries, conduct computational fluid dynamics (CFD) modeling, and build several prototypes for bench testing.
• Tax Status: All employee wages (qualified services) and ceramic powder (qualified supplies) are Qualified Research Expenses. The activities meet the four-part test as they rely on engineering and physical sciences to resolve design uncertainties.

Phase 2: Pilot Modeling and Verification (Qualified)

By early 2025, the team identifies a single design that consistently performs under test conditions. They build a “pilot model”—a full-scale, flight-ready injector—to undergo final certification.

• Activities: The pilot model is used to evaluate the design’s ultimate durability and interaction with other engine components. Technical risks regarding the manufacturing method are resolved during this phase.
• Milestone: On June 15, 2025, the Engineering Review Board signs a “Final Design Freeze” document and transfers the specifications to the production team.
• Tax Status: The costs to produce the pilot model and the certification tests are Qualified. This represents the final step of experimentation before the component meets its functional and economic requirements.

Phase 3: Transition to High-Volume Production (Excluded)

From July 2025 to December 2025, the company focuses on setting up a factory-scale assembly line.

• Activities: They purchase ten industrial 3D printers and “tool up” the software to coordinate their output. They perform several “trial production runs” to determine how many injectors can be produced per week.
• Troubleshooting: During the trial runs, they find that the 3D printers require frequent recalibration to maintain consistent wall thickness. Engineers spend 600 hours adjusting the printer settings.
• Tax Status: All activities in this phase are Excluded. The product design was already finalized; these activities are deemed post-production “tooling up,” “trial runs,” and “troubleshooting” related to production equipment.

Phase 4: Customer Adaptation (Excluded)

In 2026, a major airline customer requests a version of the Hyper-Flow injector with a different mounting bracket to fit an older engine model.

• Activities: AeroTex engineers spend three weeks modifying the mounting bracket design.
• Tax Status: This falls under the “Exclusion for Adaptation of Existing Business Components” (IRC 41(d)(4)(B)). It is Excluded because the research involves adapting a proven component to a particular customer’s requirement rather than discovering new technological information.

Phase 5: New Business Component (Qualified)

In late 2026, the company decides to develop a “Smart-Injector” that uses real-time AI to adjust fuel spray based on altitude.

• Activities: This is treated as a New Business Component. The cycle of qualified research begins again for the AI sensing feature. Even though the “Hyper-Flow” injector body is in commercial production, the “Smart-Sensing” feature is a separate business component under the shrink-back rule.
• Tax Status: Wages for the AI programmers and the engineers integrating the sensors are Qualified until the Smart-Sensing feature meets its functional requirements.

Final Thoughts and Strategic Recommendations

The exclusion for research after commercial production is a defining boundary in the Texas tax landscape, distinguishing between the state’s role as a venture-style subsidizer of innovation and its role as a collector of revenue from established industries. The passage of SB 2206 has fundamentally modernized the R&D credit, making it a permanent and more lucrative incentive, but it has simultaneously heightened the need for precise documentation and a sophisticated understanding of development milestones.

To successfully navigate this exclusion, Texas businesses must move beyond a simple “development versus sales” mindset. The “functional and economic requirements” standard used by the Comptroller and the IRS means that a project can transition into production long before the first revenue is realized. Actionable strategies for taxpayers include:

1. Establishing Formal “Design Freeze” Protocols: By documenting exactly when a design is released to production, a company can create a clear audit trail that defines the qualified period and reduces the risk of arbitrary “look-back” disallowances.
2. Utilizing the Shrink-Back Rule for Incremental Innovation: Taxpayers should not assume that the commercial status of a flagship product disqualifies all related R&D. By treating new features, sub-assemblies, or process improvements as separate business components, companies can continue to capture qualified expenses throughout a product’s lifecycle.
3. Aligning State and Federal Documentation: With Texas shifting to rolling conformity and following federal line-item reporting, it is essential that the R&D study performed for federal Form 6765 explicitly addresses the production milestones for all Texas-based projects.
4. Monitoring Combined Group Membership: Given that a change in group membership can terminate the ability to carry forward R&D credits, companies undergoing M&A activity must carefully assess the “production readiness” and “carryforward value” of the target entity’s research portfolio.

As Texas continues to position itself as a global hub for biotechnology, aerospace, and advanced manufacturing, the R&D tax credit will remain a cornerstone of its economic policy. The permanent increase in the credit rate to 8.722% and the new refundability provisions for startups provide a powerful engine for growth, provided that businesses maintain the “clear and convincing” evidence required to prove that their research is truly transformative and has not yet crossed the threshold into routine commercial production.